维力医疗2026年关注点：印尼工厂投产、关联交易及政策利好

Core Viewpoint - Vili Medical (stock code: 603309) is set to experience significant developments in 2026, focusing on capacity expansion, corporate governance, and favorable policies [1] Group 1: Company Project Advancement - The Indonesian factory is scheduled to begin small-scale trial production in March 2026 and officially start production in April 2026, with an initial capacity of 40 million units for nursing products, all supplied to major U.S. clients [2] - The second phase of the factory will involve anesthetic products and urinary catheter products, with a planned capacity of 12 million units in 2026, expected to have a limited impact on gross margin due to pricing negotiations based on costs [2] Group 2: Related Transactions - On January 9, 2026, the company held a board meeting to approve the expected annual related party transactions, with a total amount not exceeding 75 million yuan, which may affect future cash flow and business cooperation [3] Group 3: Subsidiary Development - The wholly-owned subsidiary, Langhe Medical, was re-certified as a high-tech enterprise in 2025, which is expected to enjoy tax benefits [4] - Additionally, the subsidiary Hainan Vili Medical's single-use hydrophilic coated visible nasogastric tube has been included in the fourth batch of innovative drug and medical device products in Hainan Province, benefiting from local policy support to enhance market competitiveness [4] Group 4: Company Status - The pledge situation of the controlling shareholder has improved, with 20 million shares being unpledged by Gaobo Investment on December 30, 2025, reducing the pledge rate to 28.25% as of December 31, 2025, potentially enhancing corporate governance stability [5] - The company released a profit forecast on January 7, 2026, indicating a projected net profit decline of 57%-66% year-on-year, primarily due to the decline in subsidiary operating performance and goodwill impairment, necessitating attention to the upcoming formal audit report [5]